Chenodeoxycholic acid (CDCA) has emerged as a ​critical pharmaceutical ingredient​ with expanding applications across multiple therapeutic areas. The global CDCA market, valued at approximately 300−405millionin2024−2025,isprojectedtoreach∗∗500-663 million by 2031-2033**, demonstrating a steady compound annual growth rate (CAGR) of 6.0%-6.2% . This growth is primarily driven by increasing prevalence of liver diseases, rising healthcare expenditures, and expanding applications in metabolic disorder treatments. Understanding the global buyer landscape is essential for stakeholders across the pharmaceutical supply chain. Market Overview and Key Growth Drivers Current Market Size and Projections The CDCA market has shown ​remarkable resilience​ despite global economic challenges, with the COVID-19 pandemic unexpectedly creating ​higher-than-anticipated demand​ across all regions . The market’s…